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Despite the fact that we live in an era of advanced technology and 
innovation, infectious diseases, like Tuberculosis (TB), continue to 
be one of the greatest health challenges worldwide. The main 
drawbacks of conventional TB treatment are the development of 
multiple drug resistance, resulting in high dose requirements and 
subsequent intolerable toxicity. Therefore there is a need of a new 
system  have been receiving special attention with the aim of 
minimizing the side effects of drug therapy, such as poor 
bioavailability and the selectivity of drugs. Nanoparticle-based drug 
delivery systems have considerable potential for treatment of TB. 
The important technological advantages of nanoparticles used as 
drug carriers are high stability, high carrier capacity, feasibility of 
incorporation of both hydrophilic and hydrophobic substances, and 
feasibility of variable routes of administration, including oral 
application and inhalation. Nanoparticles can also be designed to 
allow controlled (sustained) drug release from the matrix. These 
properties of nanoparticles enable improvement of drug 
bioavailability and reduction of the dosing frequency, and may 
resolve the problem of nonadherence to prescribed therapy, which is 
one of the major obstacles in the control of TB epidemics.  In this 
review, we discuss the challenges with the current treatment of the 
disease and shed light on the remarkable potential of nanotechnology 
to provide more effective treatment and prevention for TB. 
Keywords: Tuberculosis; Nanotechnology; liposome; Polymeric 
nanoparticle; non-polymeric nanoparticle.  
 
Introduction 
Tuberculosis (TB) is an infectious disease caused 
by bacteria whose scientific name is 
Mycobacterium tuberculosis [1]. It was first 
isolated in 1882 by a German physician named 
Robert Koch who received the Nobel Prize for 
this discovery. Worldwide, approximately 2 
billion people are currently infected with 
Mycobacterium tuberculosis, representing about 
30% of the global population [2]. After 
HIV/AIDS, TB is the second most deadly 
infectious disease [3]. Tuberculosis usually 
attacks the lungs but can also affect other parts of 
the body. It is spread through the air, when 
people who have the disease cough, sneeze, or 
spit [4]. Most infections in humans result in an 
asymptomatic, latent infection, and about one in 
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ten latent infections eventually progresses to 
active disease, which, if left untreated, kills more 
than 50% of its victims. 
The classic symptoms are a chronic cough with 
blood-tinged sputum, fever, night sweats, and 
weight loss. Infection of other organs causes a 
wide range of symptoms. Diagnosis relies on 
radiology (commonly chest X-rays), a tuberculin 
skin test, blood tests, as well as microscopic 
examination and microbiological culture of 
bodily fluids. Treatment is difficult and requires 
long courses of multiple antibiotics. Contacts are 
also screened and treated if necessary. Antibiotic 
resistance is a growing problem in (extensively) 
multi-drug-resistant tuberculosis. Prevention 
relies on screening programs and vaccination, 
usually with Bacillus Calmette-Guérin vaccine. 
A third of the world's population are thought to 
be infected with M. tuberculosis,[5] and new 
infections occur at a rate of about one per second 
[6]. The proportion of people who become sick 
with tuberculosis each year is stable or falling 
worldwide but, because of population growth, the 
absolute number of new cases is still increasing 
[6]. In 2007 there were an estimated 13.7 million 
chronic active cases, 9.3 million new cases, and 
1.8 million deaths, mostly in developing 
countries [7]. In addition, more people in the 
developed world are contracting tuberculosis 
because their immune systems are compromised 
by immunosuppressive drugs, substance abuse, or 
AIDS. The distribution of tuberculosis is not 
uniform across the globe; about 80% of the 
population in many Asian and African countries 
test positive in tuberculin tests, while only 5-10% 
of the US population test positive [1].  
 
Pathogenesis of tuberculosis 
 
The primary source of infection is viable 
tubercular bacilli, expelled in the environment by 
coughing, sneezing, shouting, and singing of a 
patient with active TB; the air is contaminated 
with these bacilli. Inhaled bacilli in a person are 
inoculated into his respiratory bronchioles and 
alveoli, usually towards the apex of the lung. 
When the inhaled microorganisms multiply to a 
sufficient extent, an antigen–antibody interaction 
is evoked by the cell-mediated T-lymphocytes. 
Tubercles are then formed because of 
accumulation of macrophages at the site of 
infection [8-10]. This may lead to permanent 
suppression of infection or some microbes may 
survive in the focii and may become the source of 
post primary infection when these focii break 
down under the conditions of weak host defense 
mechanisms [11,12]. This may happen 
immediately or months or years later. The hilar 
lymph nodes may get easily infected because of 
the spreading of infected macrophages having 
active bacilli. The released microorganisms are 
circulated through lymph and blood vessels to 
different parts of the body and infect-  
(i) Reticuloendothelial system (e.g., liver, spleen, 
and lymph nodes),  
(ii) Serosal surfaces and sites with high oxygen 
pressure (apices of lungs, renal cortex, and 
epiphyses of growing bones).  
Because of multiplication of organisms at these 
sites, numerous small focii develop throughout 
the body [13,14]. This type of wide-spread of 
infection is known as milliary TB. In some 
patients, the focii formation leads to temporary 
suppression of the infection, whereas 
microorganisms may still be present in the focii. 
During coughing, the caseous material containing 
microorganisms is expelled leaving cavities in the 
lungs. These active bacilli may then be 
swallowed by the same patient or inhaled by a 
healthy patient in a crowded area with poor 
personal and public hygiene resulting into 
infection of trachea, larynx, or bronchii. Infection 
of the oropharynx, larynx, and tracheobronchial 
tree respond fairly well to anti-TB drugs, whereas 
infections in the gastrointestinal tract, urinary 





The history of M. tuberculosis is very old [17]. 
Fragments of the spinal column from Egyptian 
mummies 2400 BCE show definite pathological 
signs of tubercular decay. Exact pathological and 
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anatomical description of the disease appeared in 
the 17th century. In 1882, Robert Koch’s 
scientific brilliance led to the discovery of M. 
tuberculosis as the causative agent of the disease. 
Different means of TB curtailment were 
developed from time to time. In the 19th century, 
a French bacteriologist Calmette together with 
Guerin created the Bacilli Calmette-Guerin 
(BCG) vaccine. Even though relatively 
ineffective, it is still in widespread use. In the 
20th century, during World War II, came the final 
breakthrough, the greatest challenge to the 
bacterium that had threatened humanity for 
thousands of years chemotherapy. 
 
The history of TB in India [18,19] also dates back 
to 600BC where in a Sushruta Samhita, the 
disease is known as Kshaya, ‘‘wasting disease,’’ 
or RajaYakshmaa, ‘‘the king of diseases.’’ The 
four causes of the disease proposed were 
overstrain, suppression of natural urges, wasting 
(e.g., because of grief, anxiety, or longing), and a 
promiscuous diet, any of which could cause the 
three morbid humors Vata, Pitta, and Kapha to 
flare up. A treatment based on the principles of 
Ayurveda, the classical Indian system of health 
and healing, was provided. In addition, medicines 
and dietary prescriptions were detailed. Alcohol 
in moderate quantities, the flesh of birds and 
animals, which inhibit dry areas, and goat’s milk 
were among the items recommended. TB was 
rare until the second half of the 19th century. 
Concomitant with the growing population density 
caused by industrialization, its incidence has 
increased progressively since then[20,21]. 
 
Current antituberculosis therapy 
 
Recent years have produced no radical changes in 
tuberculosis treatment for adults or children. 
However, new drugs are on the horizon, and there 
is an increasing appreciation of the special 
requirements of adults and children when 
determining drug doses. There are, at present, 
five ‘first-line’ antituberculosis agents: INH 
(isoniazid), RIF (rifampicin), PYZ 
(pyrazinamide), ETB (ethambutol), SM 
(streptomycin) and Rifabutin which is cited in 
table 1. The dearth of tuberculosis drug research 
is indicated by the fact that these agents, and the 
regimens that include them, have now been in use 
for 30 years. Recognised ‘second-line’ agents 
include ethionamide (ETH) or prothionamide, 
kanamycin (KM) or amikacin (AM), 
terizidone/cycloserine, capreomycin, viomycin 
and para-aminosalicylic acid. Without any formal 
evaluation, the fluoroquinolones have also 
attained a prominent position in regimens for the 
treatment of drug resistant tuberculosis;clinical 
studies are underway that may lead to their 
inclusion in ‘first-line’ regimens. 
INH remains the cornerstone of antituberculosis 
regimens, a position earned by its high early 
bacterial activity (EBA), outstanding 
pharmacokinetics and relatively low toxicity. 
Because of its high EBA, INH is also often the 
first agent against which resistance develops. 
Only recently has its role been questioned [22]. 
In regimens containing RMP and PZA, the 
function of INH is the rapid elimination of 
metabolically active bacilli present in 
tuberculosis cavities and the protection of 
companion drugs from resistance. Only in 
regimens not containing RMP or PZA does INH 
have a sterilising role, and this requires 12–18 
months of treatment. When the first 
antituberculosis drugs were introduced it was 
soon apparent that resistance developed 
following monotherapy with any agent, but that 
resistance could be prevented by multidrug 
therapy [23]. The major concern in early 
regimens was consequently the prevention of 
resistance. It was also known that prolonged 
therapy was required for permanent cure. As late 
as 1960, 2 years’ treatment was considered 
necessary to establish a stable cure of pulmonary 
tuberculosis [24]. It was a considerable advance 
when 6-month regimens containing RMP and 
PZA produced a stable cure with low relapse 
rates.[25] It is recommended that EMB be 
included in the 2-month ‘intensive phase’ of 
treatment with INH, RMP and PZA in areas with 
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a high incidence of initial resistance to INH, to 




                                   Drug                                Brand names [Company]                Dose(mg) 
                                       
First-line           Isoniazid               Rimifon® (Roche); Cotinazin® (Pfizer);                       300   
Drugs                                             Ditubin® (Schering) Rifampicin Rifadin®  
(Sanofi-Aventis); Abrifam®                                  300 
                                                       (Abbott); Rifaprodin®(Almirall) 
                        Pyrazinamide          Zinamide® (Merck & Co.); Pezetamid®                      500                                     
                                                 (Hefa-Frenon);  Pyrafat® (Fatol)                   
Ethambutol             Myambutol® (Dura Pharmaceuticals);                          400                           
hydrochloride         Etibi, Tibutol                                                                                                 
Streptomycin         Sesquisulfate-AgriStrep® (Merck & Co.);                    500 
                               Streptobrettin® (Norbrook) 
                         Rifabutin        Mycobutin® (Pfizer).  150 
Second-line    Clofazimine             Lamprene® (Novartis).                                                  100      
Drugs     
                       Ethionamide            Trecator® (Wyeth); Nisotin®; Trescatyl®                  500 
                                                         (M&B); Aetina®;   (Bayer).      
                       Clarithromycin         Biaxin® (Abbott); Clathromycin® (Taisho);              500  
                                                         Naxy® (Sanofi Winthrop). 
             Cycloserine               Closina®; Farmiserina® (Farmitalia);                       500 
                                                          Seromycin® (Lilly). 
                        Moxifloxacin            Actimax® (Sankyo); Vigamox® (Alcon).                 400 
                                                         Proflox® (Esteve); Octegra® (Bayer). 
                        Gatifloxacin             Tequin® (Bristol-Myers Squibb);                              400 
                                                         Zymar® (Allergan). 
                         Linezolid                  Zyvox®, Zyvoxid® (Pfizer).                                     400 
                         Capreomycin             Capastat® (Dista), Capastat sulphate®                  1000 
                                                           (Eli Lilly).                                                                 
                        p-Aminosalicylic      PASER® (Jacobus); Rezipas®.                                 500 
                           Acid                        (Bristol-Myers Squibb) 
                              
                                 Table 1- First and Second line antituberculosis drug 
Role of nanotechnology in Tuberculosis  
 
Nanotechnology is a multidisciplinary field, 
which recently has emerged as one of the most 
propitious field in tuberculosis treatment. 
Nanotechnology is definitely a medical boon for 
diagnosis, treatment and prevention of 
tuberculosis. Using nanotechnology, it has 
become possible to achieve improved delivery of 
poorly water soluble drugs, targeted delivery of 
drugs to specific cells or tissues and intracellular 
delivery of macromolecules [27]. 
Nanotechnology-based platforms for systemic 
delivery of anti-TB drugs could have similar 
advantages. Controlled-release delivery systems 
can enhance their half-lives, keeping them in 
circulation at therapeutic concentrations for 
longer periods of time. This could have major 
implications in improving adherence to the drugs. 
Nanoscale delivery systems also enhance and 
modulate the distribution of hydrophobic and 
hydrophilic drugs into and within different tissues 
due to their small size. This particular feature of 
nanoscale delivery systems appears to hold the 
most promise for their use in clinical treatment 
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Nanotechnology in tuberculosis 
diagnosis 
 Tuberculosis is diagnosed by chest radiology and 
occasionally followed by sputum collection and 
microbiological culture [28]. Radiological testing 
has low sensitivity and requires trained staff to 
operate the imaging system. Tuberculosis 
cultures are usually more sensitive than chest 
radiology but the microbiological test relies on 
bacterial growth and may take several weeks to 
yield a conclusive result [28,30]. Since 
tuberculosis is contagious, a level 3 biosafety lab 
is required for growing the cultures. These 
requirements render such diagnostic techniques 
inappropriate for the developing world. 
For latent tuberculosis, diagnosis is even more 
challenging, since typical symptoms (coughing, 
fever, sputum production, etc.) are not present. 
The tuberculin skin test (TST) is the current 
standard test for latent infection. This test 
measures an individual's immune response to 
purified protein derivative (PPD) a mixture of 
more than 200 tuberculosis antigens [31]. 
Individuals with previous exposure to the 
pathogen (e.g. latent infection) exhibit an 
immune response and the formation of an 
induration (localized inflammation) on the 
forearm where the antigens were subcutaneously 
injected. The test is inexpensive and non-invasive 
but it requires two visits within a specific time 
period to a clinic. Furthermore, the test often 
yields false positive results in patients previously 
vaccinated with the Bacillus Calmette–Gurin 
(BCG) vaccine, and false negative results in 
patients co-infected with HIV who have low T-
cell counts [29]. 
Recently, blood-based diagnostic tests with 
higher specificity have been developed to 
measure the production of INF-γ by T-cells 
following exposure to TB antigens [28]. These 
tests are known as interferon gamma release 
assays (IGRAs) [31]. A test based on enzyme-
linked immunospot assay methods (ELISPOT) is 
the T SPOT-TB test, and uses RD1 antigens to 
stimulate T-cells. ELISA-based tests include the 
Quantiferon test, which measures INF-γ 
following exposure to the PPD antibody mixture 
and the Quantiferon Gold (which uses RD1 
antigens) [30]. The RD1 antigens (CFP-10 and 
ESAT-6) are superior to PPD antibodies because 
they are specific to M. tuberculosis. As a result, 
the immune response to RD1 is also specific to 
M. tuberculosis and there is less interference 
from previous BCG vaccinations. Nonetheless, 
patients with compromised immune systems 
(e.g., patients co-infected with HIV) can give 
false negative results because these patients tend 
to have low T-cell counts. It is clear that there are  
major bottlenecks in diagnosing tuberculosis and 
that developments in the diagnosis of TB have 
been slower than other infectious pathogens. This 
presents an interesting challenge and opportunity 
for nanotechnologists. For example, the highly 
effective Quantiferon Gold assays do not react 
with PPD antibodies and do not require two 
clinical visits, but do require some laboratory 
equipment (such as an incubator). The ability of 
nanoparticles to potentially detect extremely 
small quantities of pathogens on a stand-alone 
platform may be particularly useful in the rapid 
detection of TB. 
 
Nanotechnology based drug delivery for 
TB treatment 
 
(A) Polymeric nanocarrier  
 
Dendrimer  
Dendrimers are precisely defined, synthetic 
nanomaterials that are approximately 100 
nanometres in diameter. They are made up of 
layers of polymer surrounding a central core. 
Functionality dendrimers are archetypically 
comprised of three different topological 
components of chemical significance:  a poly-
functional core, interior layers, and a multivalent 
surface. The poly-functional focal core can 
encapsulate various chemical species and exhibits 
unparalleled properties due to the special nano-
environment surrounded by extensive dendritic 
branching [32]. Due to this unique structure, 
these molecules represent attractive candidates 
for the encapsulation and delivery of anti-TB 
29 
 
Kumar et al. International Journal of Drug Delivery 3 (2011) 25-42 
 
agents for diverse administration routes, though 
only a few research works have been reported. To 
target the drug delivery to macrophages, Kumar 
et al. developed RIF-loaded mannosylated 5th 
generation (5G) PPI dendrimeric nanocarriers 
[33]. Surface modification with sugar molecules 
(e.g., mannose) recognizable by lectin receptors 
located on the surface of phagocytic cells 
improved the selective uptake of the drug-loaded 
nanocarriers by cells of the immune system. RIF 
encapsulation extents were approximately 37% 
with hydrophobic interactions and hydrogen 
bonding contributing to the physical binding of 
the drug to the core. The solubility of RIF within 
unmodified dendrimers was 52 mg/mL, while 
the superficial mannose molecules sterically 
hindered the complexation and encapsulation of 
the drug and the solubilization of RIF was 
substantially less efficient at approximately 5 
mg/mL (2-fold when compared to the aqueous 
solubility of RIF). High haemolysis levels shown 
by amine-terminated dendrimers precludes their 
clinical application. Mannosylation significantly 
reduced the haemolytic toxicity of the nano-
carrier materials from 15.6 to 2.8%. When the 
RIF-containing dendrimers were assayed, 
findings indicated a beneficial effect of the 
carrier, reducing the intrinsic haemolytic effect of 
free RIF from 9.8 to 6.5%. A similar trend was 
observed when the viability of a kidney epithelial 
cell line was tested; encapsulation improved the 
survival of the cells from 50% for free RIF to 
85%. Drug release studies conducted in vitro 
showed that the modified dendrimers sustained 
the release for about 120 h, as opposed to the fast 
delivery (b10 h) found with regular dendrimers. 
The phagocytic uptake of RIF and RIF-loaded 
dendrimers was investigated with alveolar 
macrophages harvested from rat lungs. A clear 
increase in the intracellular concentration of the 
antibiotic was apparent. 
Using a similar approach, a more recent work 
investigated the suitability of RIF-containing 4G 
and 5G PEGylated-PPI dendrimers to sustain the 
delivery of RIF [34]. PEGylation resulted in a 
significant increase of the percentage of drug 
entrapment from 28 and 39% to 47 and 61% for 
G4 and G5 derivatives, respectively. Also, the 
surface modification led to a better control of the 
release profile; i.e., 97.3 and 46.3% cumulative 
release values were respectively found for 4G 
PPI and PEG-PPI after 36 h. Finally, PEG-
grafted dendrimers showed a minimal haemolytic 
activity (1–3%) as opposed to the NH2-
terminated ones (14–20%). 
 
Cyclodextrins 
Cyclodextrins are a group of structurally related 
natural products formed during bacterial 
digestion of cellulose. These cyclic 
oligosaccharides consist of (α-1, 4)-linked α-D-
glucopyranose units and contain a somewhat 
hydrophobic central cavity and a hydrophilic 
outer surface and thus able to host other 
hydrophobic molecules [35].  
Several works reported on the complexation of 
RIF by means of different CD molecules, though 
results regarding the efficiency of this approach 
are ambiguous. Ferreira and collaborators 
prepared inclusion complexes of RIF with 
HPβCD [36]. The aqueous solubility of the drug 
increased linearly with the concentration of the 
CD, with the CD/RIF ratio in the 
complex being 1:1. Also, the solubilization was 
pH-dependent. The analysis of the chemical shift 
data of 1H and 15N NMR of free and complexed 
RIF revealed important changes in peaks of the 
side chain of the piperazine ring of the drug, 
suggesting the interaction of this region with the 
hydrophobic core of HPβCD. Koester et al. 
explained the complexation of ofloxacin with β-
cyclodextrin and the complexes showed a water 
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solubility enhancement of approximately 2.6 
times.[37]. Rao et al. carried out a comparative 
investigation of RIF complexation with β-CD and 
HPβCD in order to improve the chemical stability 
and aqueous solubility of the drug [38]. 
According to phase solubility studies, a 1:1 molar 
ratio was apparent; the stability constants found 
to be 58.13 and 76.37 for the pristine and the 
modified CD, respectively. These results 
indicated a stronger interaction between the drug 
and the HPβCD. IR spectroscopy revealed that 
the interaction was through the piperazin group 
of RIF. However, only a 2-fold solubilization 
extent was apparent with β-CD when a common 
solvent technique was employed. As opposed to 
the findings by Ferreira et al. [36], herein no 
solubility improvement of RIF was found with 
HPβCD. On the other hand, all the complexes 
improved the thermal stability of the drug. 
Additionally, when the antibacterial activity was 
assayed in M. tuberculosis, a significant decrease 
in the MIC from 64 to 32 μg/mL was observed, 
this phenomenon likely due to a better 
permeation of the drug through the wall of the 
bacilli. Another drawback to the low aqueous 
solubility of a drug is the inability to conduct 
preliminary biological and clinical evaluations of 
new drug candidates [39]. In this context, the 
poorly-water soluble nitroimidazole P-824, a new 
anti-TB drug under study, has shown activity 
against drug-sensitive and multi-drug resistant 
bacilli. Aiming to conduct in vivo experiments in 
a short-course murine infection model, a complex 
with HP-γ-CD was developed and a 
cyclodextrin/lecithin formulation prepared [40]. 
A reduction in the bacterial load in the lungs was 
observed with 50 and 100 mg/kg doses. CD have 
been also investigated as carriers for local 
delivery to the lung [41]. 
 
Polymeric micelles  
Polymeric micelles are nanocarriers generated by 
the self assembly of amphiphilic polymers in 
water above the CMC [42]. The hydrophilic 
blocks are exposed to the aqueous medium 
forming the micellar shell that facilitates the 
solubilization of the amphiphile in water and 
stabilizes the aggregate. In contrast, the 
hydrophobic blocks form the inner micellar core, 
a hydrophobic domain that enables the 
incorporation of poorly-water soluble drugs by 
physical interaction or chemical conjugation 
leading to higher solubility extents [43]. 
Commercially available and FDA-approved 
poly(ethylene oxide)–poly(propylene oxide) 
(PEO–PPO) block copolymers (linear 
poloxamers and branched poloxamines) are 
among the most important micelle-forming 
materials [44]. Preliminary studies that 
investigated the solubilization of RIF within 
polymeric micelles of a variety of linear and 
branched PEO–PPO with a broad spectrum of 
compositions showed a minimal solubilization 
effect ( 2-fold) [45]. These findings suggest that 
the size of the micellar core strongly limits the 
incorporation of the extremely bulky RIF 
molecule. Other amphiphilic block copolymers 
synthesized by linking mono and bifunctional 
PEG precursors of different molecular weight 
with PCL enabled the fine tuning of the HLB and 
the enlargement of the micellar core, improving 
the solubilization extent 5- to 7-fold [45]. 
 The micelle-forming prodrug showed a 5.6-fold 
increase in antituberculosous activity against M. 
tuberculosis in vitro when compared to the free 
drug. The mechanism would primarily involve 
the micelle uptake and the latter intracellular 
release of the drug after the hydrolysis of the 
linkage. The same synthetic pathway was 
pursued in order to encapsulate PYZ [46,47] and 
RIF [47]. The size of themicelles would prevent 
renal filtration, increasing the residence times in 
the blood stream. Moreover, a stronger 
antimycobacterial activity was apparent. To 
overcome resistance, Jin and collaborators 
designed INH lipid derivatives [48]. The new 
amphiphilic molecules formed monolayers at the 
air/water interface. The aggregation behavior was 
intimately related to the character of the 
hydrophobic tail. Flexible medium-long tails 
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formed nano-sized vesicles. In contrast, short 
lipid tail-derivatives displayed weak hydrophobic 
interactions and they did not self-assemble. 
Molecules with very long tails led to the 
formation of crystal-like structures. Finally, they 
showed promising antibacterial activity against 
Mycobacterium due to a more lipophilic structure 




PNP have been extensively explored as means for 
drug solubilization, stabilization and targeting 
[49,50]. Depending on the technology employed 
for their production, two kinds of systems can be 
generated, namely nanocapsules and 
nanospheres. In the former, the drug solubilized 
in aqueous or oily solvents is surrounded by a 
polymeric membrane. In contrast, the latter is 
comprised of solid matrices of variable porosity 
where the active molecules are homogeneously 
distributed through the particle and, often, 
dispersed at the molecular level. A broad 
spectrum of biomaterials is available for the 
production of PNP [51]. Advantageous features 
such as high stability, high loading capacity of 
hydrophilic and hydrophobic drugs and 
feasibility of administration by different routes 
have made PNPs one of the most popular 
approaches for drug encapsulation [51]. PNP are 
removed from the body by opsonization and 
phagocytosis [52]. In order to prevent recognition 
by the host immune system and to prolong 
circulation times in the blood stream, the 
modification of the surface with highly 
hydrophilic chains (e.g., polyethylene glycol) has 
been pursued. This approach has been one of the 
most extensively investigated with respect to 
antituberculosis drug delivery systems. 
Anisimova et al. investigated the encapsulation of 
RIF, INH and streptomycin within PBCA and 
PIBCA nanoparticles and tested the accumulation 
in human blood monocytes in vitro toward the 
development of a drug depot [53]. Encapsulated 
INH, streptomycin and RIF showed 4–8-, 7- and 
22–25-fold increases in the intracellular 
concentration with respect to the extracellular 
concentration. In contrast, free INH and RIF 
showed intracellular levels similar to and 5 times 
higher than the extracellular concentration, 
respectively. Streptomycin was not detectable. 
More recently, moxifloxacin-loaded PBCA NPs 
were produced by means of the anionic 
polymerization of poly(butyl-2-cyanoacrylate) in 
the presence of the drug [54,55]. Cytotoxicity 
studies indicated that the moxifloxacin loaded 
NPs were more toxic to the macrophages than the 
free drug [54].When infected cells were exposed 
to the drug in the free and the encapsulated form, 
a pronounced increase in the intracellular 
concentration from 125–175 to 375 μg/mL was 
found [54]. These results relied on the NP uptake 
by the phagocytic cells. In addition, encapsulated 
moxifloxacin was more effective than the free 
form to kill intracellular bacilli [54]. Evaluation 
of the anti-TB activity in mice infected with M. 
tuberculosis showed a significant decrease in the 
mycobacteria count in the lungs after IV 
administration [55]. More recently, the 
encapsulation of different first-line anti-TB drugs 
(RIF, INH and PYZ) within biodegradable PLGA 
nanoparticles was investigated by Khuller's group 
[56]. Findings showed that, as opposed to the 
biodistribution profile observed for the free drugs 
that were cleared from circulation after 12–24 h, 
nanoencapsulated drugs were detected in plasma 
for up to 9 days and therapeutic concentrations in 
tissues were maintained for 9–11 days. Khuller et 
al. also produced anti-TB drug-loaded alginate 
nanoparticles (235 nm diameter) by means of 
ionotropic gelation [57]. Encapsulation efficiency 
ranged between 80–90% for RIF, 70–90% for 
INH and PYZ and 88–95% for ETB. 
 
 
 (B)Nonpolymeric nanocarrier 
 
Liposome 
Liposomes, ranging in size between 25 nm and 
several microns, are microscopic vesicles that 
comprise one or more phospholipid bilayers 
which surround an aqueous core [58]. They are 
prepared from natural or synthetic phospholipids 
and cholesterol, and may also additionally 
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include other lipids and proteins. The aqueous 
core facilitates the entrapment of hydrophilic 
drugs, while hydrophobic drugs are bound to or 
incorporated in the lipid bilayer. When 
administered, liposomes are recognised as being 
foreign, and are immediately taken up by cells of 
the mononuclear phagocytic system (MPS). In 
order to prevent elimination and extend 
circulation times, liposomes are usually 
PEGylated. A pioneering work explored the 
incorporation of gentamicin into liposomes and 
compared the antibacterial activity to that of the 
free drug in a mouse model of disseminated M. 
avium complex infection [59]. The encapsulated 
drug significantly reduced the bacterial count in 
spleen and liver. In addition, a dose-related 
reduction of the bacterial load, though no 
sterilization, was found. Similar results were 
obtained with different liposome-entrapped 
second-line antibiotics [60-62]. Deol and Khuller 
produced lung-specific Stealth® liposomes made 
of phosphatidylcholine, cholesterol, 
dicetylphosphate, O-steroyl amylopectin and 
monosialogangliosides/distearylphosphatidylet- -
hanolamine- poly(ethylene glycol) 2000 for the 
targeted delivery of anti-TB drugs to the lung 
[63]. Biodistribution experiments of different 
liposome types were conducted in healthy and 
tuberculosis infected mice after IV injection. 
Findings showed a pronounced increase from 
5.1% with conventional liposomes to 31% with 
PEGylated systems containing O-steroyl 
amylopectin in the accumulation of the 
nanocarriers in the lungs after 30 min. The 
accumulation extent was associated to the 
composition of the vesicles. Moreover, 
pretreatment of both healthy and infected animals 
with conventional liposomes (1 h before the 
administration of modified liposomes) saturate 
the reticulo-endothelial system and the uptake 
levels in the lungs rose to approximately 40% for 
the modified nanocarriers, after 30 min. On the 
contrary, modified liposomes showed reduced 
(30– 50%) uptake and accumulation in the liver 
and spleen. Also, the biodistribution in the 
different organs was similar in both animal 
groups. The extent of drug incorporation was 8–
10 and 44–49% for INH and RIF, respectively. 
The cytotoxicity of the drug-loaded nanocarriers 
was evaluated in peritoneal macrophages and 
compared to that of the free drugs. A significant 
decrease in the toxic effects was observed. This 
phenomenon was associated with a more 
controlled release of the drug. Evaluation of the 
hepatic activity following the administration of 
the free and the encapsulated drugs indicated a 
statistically significant decrease in the hepatoxic 
activity of the anti-TB agents upon encapsulation. 
Then, the therapeutic activity of free and 
encapsulated INH and RIF was evaluated in both 
therapeutic and sub-therapeutic dose [64]. A 12 
mg/kg dose of free INH reduced the number of 
CFU in the lungs to about 4.5 log units, while the 
liposomal drug resulted in a decrease to 3.9 log 
units. A 10 mg/kg free and encapsulated RIF 
dose reduced the CFU to 4.3 and 3.8 log units, 
respectively. A similar trend was observed in the 
liver and spleen. Moreover, administration of 
sub-therapeutic doses (4 and 3 mg/kg for INH 
and RIF respectively) led to a higher decrease in 
CFU, as compared to the free drugs administered 
at a therapeutic concentration. Overall, a 
significant increase in the anti-TB activity was 
found.  
With the aim of improving the anti-TB activity, 
reducing the toxicity and enabling the parenteral 
administration of highly lipophilic clofazimine, 
drug-loaded liposomes were produced [65] and 
preclinically evaluated in acute and chronic 
murine infections [66]. Encapsulation reduced the 
in vitro and in vivo toxicity of the drug and 
enhanced the anti-TB activity in both acute and 
chronic models. This inhibition was markedly 
higher in the liver and lung. In addition, 
chronically infected mice treated with the 
encapsulated drug showed total clearance from 
the liver and spleen with no signs of recovery 2 
months post-treatment. In the lungs, a gradual 
decrease in CFU was observed, though a rebound 
was found 2 months post-treatment. Regardless 
of the apparently total clearance of the bacilli 
following a second treatment with the liposomal 
drug, a similar phenomenon was observed after 2 
months. In more recent investigations, PYZ- [67] 
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and rifabutin containing liposomes [68] were also 
produced, stressing the great versatility and 
potential of these nanocarriers. 
 
Nanoemulsion 
Nanoemulsions are transparent or translucent oil-
in-water (o/w) or water-in-oil (w/o) droplets with 
a mean droplet diameter between 10-100 nm 
[69]. Nanoemulsions are also known as 
submicron emulsions, mini-emulsions, ultrafine 
emulsions, and unlike the thermodynamically 
stable microemulsions, nanoemulsions are 
kinetically stable with great stability in 
suspension due to their small droplet size. Due to 
their small droplet size, nano-emulsions may 
appear transparent, and Brownian motion 
prevents sedimentation, creaming and 
flocculation hence offering increased stability. In 
contrast to microemulsions, nanoemulsions are 
metastable and can be diluted with water without 
changing the droplet size distribution [70]. In the 
recent studies nanoemulsions are of considerable 
interest in anti- 
tubercular drug delivery.  
Ahmed and co-workers developed different o/w 
nanoemulsions of RIF for IV administration 
using pharmaceutically acceptable excipients: 
Sefsol® 218 as the oil phase, Tween® 80, 
Tween® 85 and saline water as the surfactant, the 
cosurfactant and the aqueous phase [71].The 
mean droplet size ranged between 47 and 115 
nm, the lower sizes being for systems containing 
lower oil contents. The entrapment efficiency 
was over 99% and the visual homogeneity was 
excellent for all the nanoemulsions. In vitro drug 
release studies indicated an initial burst effect 
ranging from 40 to 70% after 2 h, followed by a 
more moderated release afterwards. Finally, 
stability assays over 3 months indicated slight 
increases in the droplet size and the viscosity of 
the systems at 4 and 25 °C. 
 
Nanosuspensions 
Nanosuspensions are sub-micron colloidal 
dispersions of pure drugs stabilized with 
surfactants [72]. Nanonization (reduction of the 
average size of solid drug particles to the nano-
scale generally by top milling or grinding) is a 
useful methodology to improve the solubility of 
drugs displaying strong solute–solute interactions 
and high melting points and, in general, both poor 
water and lipid solubility. The solid and dense 
states of the pure drug particles confer a maximal 
mass per volume ratio, especially critical in 
systems demanding high drug loadings. Despite 
its potential, only a few studies aiming to 
optimize the pharmacotherapy of tuberculosis 
have been reported. Peters and collaborators 
developed a clofazimine nanocrystalline 
suspension in order to overcome the toxicity and 
the low solubility (0.3 μg/mL) of the drug [73]. 
To evaluate the suitability of the formulation for 
IV administration they compared the 
effectiveness of the nanosuspension in the 
treatment of murine Mycobacterium avium 
infection to that of drug-loaded liposomes. 
Application of 10-cycle discontinuous and 
continuous homogenization processes resulted in 
particles of 600 and 300 nm, respectively, both of 
which are small enough to prevent capillary 
embolism (less than 5 μm). At approximately 100 
nm, the clofazimine-loaded liposomes included in 
the study were substantially smaller and these 
liposomes showed preclinical effectiveness 
despite limited physical stability over time, 
difficult reconstitution of freeze-dried samples 
and low drug loading capacity. An extensive size 
and size distribution characterization indicated 
that the nanosuspensions display more 
homogeneous size distributions, lower amounts 
of sub-2 and -5 μm particles and physical 
stability for more than 2 years. In vivo assays 
were conducted and shows continued treatment 
led to a significant reduction of bacterial counts 
in all the organs evaluated. Effectiveness levels 
were comparable to those of liposomal 
clofazimine, however, the ease of preparation and 
the higher physical stability of the 
nanosuspension were distinguishing. Reverchon 
et al. used supercritical carbon dioxide-assisted 
atomization to produce RIF sub-micronic 
particles of controlled size and size distribution 
that fit the range of injectable [74] and 
aerosolizable drug delivery systems(b5 μm) [75]. 
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Of the different solvents used to solubilize the 




Niosomes are thermodynamically stable 
liposome-like vesicles produced with the 
hydration of cholesterol, charge-inducing 
components such as charged phospholipids (e.g., 
dicethylphosphate and stearyl amine) and non-
ionic surfactants (e.g., monoalkyl or dialkyl 
polyoxyethylene ether) [76]. They were 
conceived as alternative DDS that overcome a 
number of drawbacks shown by the liposomes, 
which were mainly associated with sterilization, 
high production costs, scale-up difficulties and 
the instability of the phospholipidic components 
after light exposure even at room temperature. 
Niosomes can host hydrophilic drugs within the 
core and lipophilic ones by entrapment in 
hydrophobic domains. In an early study, Jain and 
Vyas prepared micro-sized (8–15 μm) RIF-
loaded niosomes containing Span 85 as the 
surfactant [77]. In vivo studies showed that by 
adjusting the size of the carrier, up to 65% of the 
drug can be localized in the lungs. In a more 
recent investigation, the same group of scientists 
extended the investigations and evaluated the 
biodistribution of niosomes with smaller sizes (1–
2 μm) produced with different sorbitan esters 
(Span® 20, 40, 60, 80 and 85) and cholesterol in 
a 50:50 percent mol fraction ratio [78]. The 
entrapment extents gradually increased with the 
increase of the hydrophobicity of the surfactant 
and ranged between 20 and 35%. In vitro release 
studies showed 80% maximal and 52% minimal 
levels for Span-20- and Span-85-based systems, 
respectively; the more lipophilic the surfactant 
was, the slower the drug release in the aqueous 
medium. Niosomal formulations attained 
substantially higher RIF concentrations in 
thoracic lymph nodes via the i.p. route (46.2% of 
the administered dose) as opposed to 13.1% for 
the free drug. These findings suggested that 
compartmentalization of the drug took place in 
the lymphous tissue. In contrast, when the drug-
loaded carriers were injected intravenously, only 
7.3% of the drug was found in the thorax, with 
the accumulation extent being lower than the 
11.5% obtained by free RIF. 
Mullaicharam and Murthy studied the organ 
biodistribution of RIF niosomes (5 mg/mL) 
following IV and i.t. administration and 
compared it to that of the free drug in albino rats 
[79]. In general, a significant increase in the total 
drug concentration in the lungs, liver, kidneys 
and blood serum was apparent for rifampicin-
loaded niosomes. After IV, niosomes 
preferentially accumulated in the lung, liver and 
kidney with the organ to serum AUC ratios being 
117,060 for lung/serum, 67 for liver/serum and 
3068 for kidney/serum. In contrast, 
administration of free RIF resulted in a less 
selective delivery (558.3 for lung/serum, 16.1 for 
liver/serum and 332.6 for kidney/ serum). After 
i.t. administration, the lung/plasma ratios were 
128,585 and 885 for niosomes and free drug, 
respectively, representing a 145- fold increase in 
the accumulation capacity of RIF-loaded 
niosomes in the lungs as compared to the free 
drug. 
 
Solid lipid nanoparticles (SLN) 
Solid lipid nanoparticle(SLN) dispersions have 
been proposed as a new type of colloidal drug 
carrier system suitable mainly for intravenous 
administration.The system consists of spherical 
solid lipid particle in the nanometer range, which 
is disperse in water or in aqueous surfactant 
solution.Generally they are made of solid 
hydrophobic core having a monolayer of 
phospholipid coating. The solid core contains the 
drug dissolved or dispersed in the solid high 
melting fat matrix. The hydrophobic chains of 
phospholipid are embedded in the fat matrix 
.They have potential to carry lipophilic or 
hydrophilic drug or diagnostics. SLN not only 
combine the advantages of traditional colloidal 
drug carrier systems like liposomes, polymeric 
nanoparticles and emulsions but also avoid the 
problems associated with them [80]. 
The antitubercular drug loaded SLNs were 
prepared by the emulsion solvent diffusion 
technique to co-incorporate rifampicin, isoniazid 
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and pyrazinamide. The chemotherapeutic 
potential of the formulation was evaluated via the 
respiratory route in the guinea pigs. It was 
observed that a sustained drug release was 
maintained for 5 days in plasma and for 7 days in 
the organs. The pharmacokinetics was unaltered 
in healthy as well as TB infected guinea pigs. 
Seven weekly doses in the organs of TB infected 
guinea pigs, replacing 46 conventional doses. 
This was the first report of the chemotherapeutic 
efficacy of SLNs in experimental TB[81] .Next 
the studies were carried out via the oral route and 
better results were obtained as the drug levels 
could be maintained in the plasma for 8 days and 
in the organs for 9-10 days. Five oral doses of  
the formulation spaced 10 days apart were as 
efficacious as 46 doses of oral free drugs in terms 
of producing bacterial clearance in TB infected 
mice [82]. 
 
Local delivery of anti-TB drugs to the 
lung 
The potential advantages of direct delivery of the 
TB drug to the lungs include the possibility of 
reduced systemic toxicity, as well as achieving 
higher drug concentration at the main site of 
infection. Moreover, in contrast to the oral route 
of administration, inhaled drugs are not subjected 
to first-pass metabolism. A possible obstacle to 
using nanocarriers for pulmonary delivery is that 
their mass median aerodynamic diameter, an 
essential parameter for the particle deposition in 
the lungs, is often too small. 
Nevertheless, the effectiveness of pulmonary 
drug delivery using nanoparticles was 
demonstrated in a number of studies [83]. The 
pharmacokinetics and antibacterial effect of the 
nanoparticle bound anti-TB drugs administered 
via respiratory route was investigated in guinea 
pigs [84]. The dose was delivered via a suitable 
facemask connected to the compressor–nebulizer 
system. A single nebulization of RIF, INH, and 
PYZ coencapsulated in PLG nanoparticles to 
guinea pigs resulted in sustained therapeutic drug 
levels in the plasma for 6 to 8 d and in the lungs 
for up to 11 d. This effect was similar to that 
obtained after oral administration of the 
nanoparticulate formulation of the same drugs. In 
nebulization of nanoparticles to M. tuberculosis– 
infected guinea pigs at every 10th day, no 
tubercle bacilli could be detected in the lung after 
only five doses of treatment, whereas 46 daily 
doses of orally administered drug were required 
to obtain an equivalent therapeutic benefit. 
Administration to infected guinea pigs of 
nebulized RIF, INH, and PYZ coencapsulated in 
wheat germ agglutinin– functionalized PLG 
nanoparticles was even more effective: three 
doses administered fortnightly for 45 d were 
sufficient to produce a sterilizing effect in lungs 
and spleen [85]. A sterilizing effect was also 
achieved when the drugs were loaded in solid 
lipid nanoparticles [86]. No tubercle bacilli could 
be detected in the lungs/spleen after seven doses 
of treatment of infected guinea pigs with drug-
loaded solid lipid nanoparticles. It is noteworthy 
that the solid lipid nanoparticles display 
important advantages, such as the composition 
(physiologic compounds) and the possibility of 
large-scale production favored by the feasibility 
to avoid organic solvents in the manufacturing 
process [87]. 
 
Nanotechnology based vaccines for 
tuberculosis treatment 
 
The aerosol vaccine- under development through 
collaboration between Harvard University and 
the international not-for-profit Medicine in Need 
(MEND) could provide a low-cost, needle-free 
TB treatment that is highly stable at room 
temperature. While most new TB vaccines 
continue to call for needle injection, but this new 
vaccine could provide safer, more consistent 
protection by eliminating these injections and the 
need for refrigerated storage. A successful result 
of aerosol delivery using nanoparticle technology 
offers a potentially new platform for 
immunization. Among guinea pigs vaccinated 
with the aerosol treatment and subsequently 
exposed to TB, less than 1 percent of lung and 
spleen tissue showed effects of the disease. By 
contrast, in animals treated with the same dose of 
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the traditional injected vaccine, some 5 percent of 
lung tissue and 10 percent of spleen tissue 
showed symptoms following TB exposure.  
In the aerosol vaccine, particles form at 
micrometer and nanometer scales and in spherical 
and elongated shapes, a combination that appears 
to improve dispersal in the mouth. While 
commonly used with food, cosmetics, and 
pharmaceuticals, this spray drying of small and 
large molecules is seldom used for drying cellular 
material. The new technique enables TB 
vaccines, and potentially other bacterial and 
viral-based vaccines, to sidestep the traditional 
problems associated with keeping vaccines 
chilled. Furthermore, a nanotechnology-based 
vaccine adjuvant for TB was developed by the 
U.S firm, Biosante, in 2002 [88]. 
 
CONCLUSIONS 
Although identifying novel anti-TB agents 
remains a priority, the development of the 
nanoparticle-based delivery systems for currently 
used agents may represent a cost-effective and 
promising alternative. The above data suggest 
that nanoparticles have a considerable potential 
for treatment of TB. Their major advantages, 
such as improvement of drug bioavailability and 
reduction of the dosing frequency, may create a 
sound basis for better 
management of the disease, making directly 
observed treatment more practical and affordable. 
Another important advantage of the nanoparticles 
is the feasibility of the versatile routes of drug 
administration, including oral and inhalation 
routes. In addition, high stability of the 
nanoparticles suggests long shelf life. 
It can be expected that future research will 
concentrate on the development of the vectorized 
delivery systems combining advantages of the 
colloidal carriers, such as large payloads of a 
drug, with active targeting to the infection sites. 
Moreover, development of innovative 
formulation technologies suggests that 
nanoparticles can be incorporated into various 
solid dosage forms (microparticles, granules, or 
tablets), which can release the nanoparticles at 
the site of action, preserving their original 
properties. These approaches would further 
improve efficacy and practicability of the 
nanoparticle-based formulations. 
Finally, the success of this technology will 
probably depend on toxicologic issues associated 
with understanding of the fate of nanocarriers and 
their polymeric constituents in the body, as 
well as elimination of the risk of the residual 
organic solvents. However, further research is 
necessary in order to bring nanoparticulate 
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